Intuitive (ISRG) Q2 2026 earnings review
Strong Quarter, Softer Core: Revenue Beats While US Procedures Slow
Intuitive delivered another financially excellent quarter: revenue grew 19% to $2.89B, non-GAAP EPS jumped 28% to $2.80, and gross margin hit 70% (68.7% excluding a one-time $36M tariff refund). Capital demand was strong — 468 da Vinci placements, up 18%. But the growth engine is downshifting: US da Vinci procedures slowed from 14% to 12% as patients defer care amid ACA subsidy changes, and management now points to the midpoint of its 13.5–15.5% full-year procedure guide, implying further deceleration in H2. Gross margin guidance was raised to 68–69%, but buybacks nearly stopped ($0.38B vs $1.1B in Q1), and a new instrument Extended Use Program will pressure the key recurring revenue line in 2027 — by an amount management refuses to quantify until next quarter.
🐂 Bull Case
Revenue keeps growing ~4 points faster than procedures thanks to da Vinci 5 pricing ($1.6M ASP), leasing revenue (+22%), and service revenue per system (+8%). Operating margin hit 42% — the model converts every procedure into more dollars.
Q1's placement dip proved to be seasonality, not demand pull-forward: Q2 placements rose 18% YoY with trade-ins up 73%. Japan responded immediately to new June 1st reimbursement (25 systems vs 15), and ASC placements hit a record 27.
Cardiac procedures accelerated to +39%, nipple-sparing mastectomy +43%, SP +61% with stapler adoption jumping to 60% of eligible US cases, and a new GI robotic endoscope was submitted to the FDA — a potential new platform beyond surgery and lung biopsy.
🐻 Bear Case
US da Vinci growth fell to 12% from 14% in Q1 and 16% a year ago. Management blames deferrable procedures and ACA premium changes — but deferral is a claim that can't be verified until patients actually return, and other med-tech companies aren't reporting the same effect.
The Extended Use Program will cut customer cost per procedure on core instruments starting H1 2027. The 2020 precedent cost roughly 7 points of I&A per procedure. Management declined to quantify the impact twice on the call — the number arrives next quarter.
Just $0.38B repurchased at $439/share average, versus $1.1B in Q1. The company bought less stock at cheaper prices — a curious signal from a team that called earlier repurchases 'opportunistic during volatility.'
⚖️ Verdict: ⚪
Neutral-positive. Backward-looking metrics are excellent — margins, cash flow, capital placements all strong. But the forward picture is softer: decelerating US procedures, guidance steering to midpoint, and an unquantified 2027 instrument pricing reset. The quality of the franchise is not in question; the pace of the core engine is.
Key Themes
US Procedure Deceleration: ACA Deferral or Something Structural?
US da Vinci growth slowed to 12% (from 14% in Q1, 16% in 25Q3). Management attributes it to patients deferring elective care as enhanced ACA premium subsidies expired, noting deferrable benign procedures moderated while non-deferrable ones held. The defense: disease burden is unchanged and deferred patients eventually return. The problem: this can't be verified for quarters, analysts noted other med-tech firms aren't calling it out, and management admitted it has no precise estimate of its ACA/Medicaid exposure. If the real cause is market maturation ('law of large numbers,' which the CFO himself mentioned), the recovery never comes. This is now the single most important variable in the model.
Extended Use Program: Trading Near-Term Revenue for Long-Term Adoption
Starting H1 2027, a subset of EndoWrist instruments will get more uses per instrument at lower cost per use — deliberately reducing I&A revenue per procedure to unlock cost-sensitive benign procedures, ASCs, and international markets. The 2020 predecessor program cost ~7 points of I&A per procedure. Management refused to quantify this round twice on the call, promising numbers next quarter. Force feedback, stapling, and energy products are excluded, and accretive da Vinci 5/SP mix partially offsets. Strategically sound — the same playbook announced alongside new instrument encryption technology, a one-two response to third-party instrument remanufacturers. But until quantified, 2027 I&A models are guesswork.
Capital Cycle Strength: Q1 Placement Dip Was Noise
468 da Vinci placements (+18% YoY) with 246 da Vinci 5 systems resolved the question raised by Q1's sequential drop — there was no demand pull-forward. US placements rose 24% to 267, almost entirely driven by trade-ins (144 vs 83), confirming the dV5 upgrade cycle has years to run: management referenced the Xi cycle taking ~7 years to peak, and dV5's installed base of 1,700 sits against 11,710 total systems. Refurbished system demand exploded — 64 refurbished Xi placements vs 10 a year ago — powering record ASC penetration (27 placements, 20 of them XiR) and distributor market share defense (71 systems placed).
Ion Growth: Sixth Straight Quarter of Deceleration
Ion procedures grew 36% — healthy in isolation, but the sequential pattern is unbroken: 52% → 52% → 44% → 39% → 36% over five quarters. Placements were flat at 55 vs 54 a year ago. Management points to utilization focus (+11%) and international expansion (now 12 countries), with ROSE and EBUS integrations in development but not landing in 2026. The US biopsy indication appears to be maturing faster than new growth vectors arrive. Cumulative procedures crossed 400,000.
SP Platform: The Fastest Horse Keeps Running
SP procedures grew 61%, with US average system utilization up 25% from Q1's pace. The SP stapler is the adoption catalyst: used in nearly 60% of eligible US cases, up from under 40% last quarter, now in broad launch across Europe and Korea with Japan coming in Q3. 38 systems placed (vs 23), installed base at 445. Early momentum in Europe, Japan, and Taiwan adds geographic legs to what was once a Korea-centric story.
Margin Engine: Cost Reductions Doing the Heavy Lifting
Non-GAAP gross margin of 70.0% included a $36M one-time IEEPA tariff refund; the clean 68.7% still beat the prior 67.5–68.5% guide and drove a raise to 68–69% for the year. Drivers: product cost reductions, fixed overhead leverage from new facilities, and da Vinci 5 contribution margins already matching mature Xi levels. Non-GAAP operating margin reached 42% as revenue grew 19% against 13% OpEx growth — with R&D deliberately growing faster than SG&A. The 1.0% tariff drag persists, but the >70% mid-term margin goal looks closer than it did two quarters ago.
Japan Turns, China Grinds
Japan's new reimbursement policies took effect June 1st — coverage for additional procedures (bilateral inguinal hernia the largest) plus economic incentives for higher-utilization programs. Placements responded immediately: 25 systems vs 15 a year ago. Management is measured on pace but the direction has flipped after six quarters of capital weakness. China remains the mirror image: 2 systems placed, lower tender activity, domestic competition, and pricing pressure. The government's tender centralization is being framed by management as favoring strong robotic programs rather than a value-based-procurement squeeze — a claim to monitor, not accept. Green Channel processes for SP and da Vinci 5 continue; neither is cleared in mainland China.
My Intuitive+ Renewals: Small Cohort, Perfect Retention
The first wave of paid My Intuitive+ renewals executed in Q2 — the digital subscription bundling telepresence, simulation, and AI-driven case insights on da Vinci 5. The cohort was small, but zero customers opted out. No revenue disclosure yet, so the high-margin recurring stream remains unquantified, but a 100% initial renewal rate is the single best early datapoint the subscription thesis could have produced.
Capital Strength vs Procedure Softness: The Dichotomy
A concern hiding inside the strong placement numbers: roughly half of US Q2 placements were trades, which don't expand the installed base, and management acknowledged US installed base expansion has moderated for several quarters. System utilization — the honest demand metric — grew just 3%. Strong capital numbers today are partly hospitals upgrading existing capacity, not adding it. If procedure growth keeps slowing while systems keep shipping, utilization compresses, and utilization is what drives the 85%-recurring-revenue engine. Management flagged some customer caution on ACA enrollment trends that hasn't yet reached the capital pipeline.
GLP-1s Still Eroding Bariatrics
US bariatric procedures declined high single digits — now a seven-quarter trend with no bottom called. The category is under 3% of da Vinci procedures, so the direct damage is contained, but it remains the live test case for whether pharmacological substitution can reach other procedure categories. The full-year guidance range explicitly includes obesity drugs among its risk factors.
Other KPIs
Up 71% versus 1H 2025 — cash generation is accelerating faster than earnings. Cash and investments ended at $8.63B, rising $0.65B in the quarter despite $379M of buybacks and $112M of capex. The company remains debt-free with capital returns funded entirely from operations.
Up from $1,800 a year ago (force feedback, SP and dV5 mix) but down from $1,880 in Q1, attributed to elevated Q1 distributor ordering, more colectomy, and fewer bariatric procedures. This metric now carries double weight: it is the line the 2027 Extended Use Program will deliberately pressure, and quarterly noise from 'ordering patterns' will make the underlying trend harder to read. Watch whether the sequential decline repeats in Q3.
Leasing deepened further: 54% of da Vinci placements were leases, leasing revenue grew 22% on a 15% larger leased base and 7% higher revenue per system (dV5 mix). Service revenue per system rose 8%. The business keeps shifting from capital sales toward annuity economics — which is exactly why procedure growth, not placements, is the metric that matters.
A sharp slowdown from Q1's $1.1B, executed at lower average prices than earlier repurchases (Q3 2025: ~$480/share). Cash built up $0.65B in the quarter instead. Either management is husbanding capital for R&D-heavy programs like the GI platform, or the 'opportunistic' framing of prior buybacks deserves a discount. One quarter isn't a pattern; two would be.
Guidance
Decelerating. The range is unchanged from April, but the new midpoint language is a soft downgrade after Q1's raise. First-half growth ran ~15%, so a ~14.5% full year implies H2 slowing toward ~14% — with management flagging a tougher US comp in Q3 plus holiday timing effects internationally. The range still carries five named risks: ACA premium changes, China tenders, European capital budgets, Japan's recovery pace, and GLP-1s.
Raised from 67.5–68.5% — the second consecutive raise this year (original January guide: 67–68%). Accelerating margin trajectory driven by product cost reductions and overhead leverage, partially offset by 1.0% tariff drag, freight and semiconductor memory inflation, newer-product mix, and facility depreciation. The raise came even before the one-time tariff refund benefit, which is excluded from the guide.
Narrowed from 11–14%, cutting the top end. Combined with the gross margin raise, the full-year operating margin outlook improved on both lines. R&D continues to grow faster than SG&A by design — funding the GI platform, cardiac instruments, and the 100-update da Vinci 5 software cadence. A $70M foundation contribution made in Q4 2025 will not repeat.
Key Questions
Extended Use Program: The Missing Number
The 2020 program cost roughly 7 points of I&A per procedure. What is the 2027 impact of this round, how much is offset by force feedback and dV5/SP mix, and what incremental procedure volume is assumed in return? This is the biggest open variable in next year's model.
Proving the ACA Deferral Thesis
Management asserts deferred patients will return because disease burden is unchanged. What specific evidence would confirm or refute this by Q4 — and how would management distinguish deferral from market maturation, which the CFO himself acknowledged as a contributing factor?
Why Did Buybacks Slow at Lower Prices?
$0.38B repurchased at $439/share average versus $1.1B in Q1 at higher prices, while cash built to $8.6B. Is capital being reserved for M&A or the GI program, or has the appetite changed?
China Tender Centralization: Real Exposure
Management says the centralized tender process is not comparable to volume-based procurement and may favor strong robotic programs. What happens to pricing and win ratios if that optimistic read is wrong, and how much of the ~273-system quota remains addressable?
Utilization vs Placements
US installed base expansion has moderated and utilization grew only 3%. If procedure growth lands at guide midpoint while placements stay strong, does utilization decline in 2027 — and what does that do to usage-based lease revenue?